Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naproxen + domperidone
- Development stage
- Unknown
- Lead developer
- Brainwave
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose combination of the non-steroidal anti-inflammatory drug (NSAID) naproxen and the dopamine D2 receptor antagonist domperidone, marketed by Brainwave Healthcare. Naproxen provides analgesic and anti-inflammatory effects by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, thereby reducing the synthesis of prostaglandins involved in migraine pain. Domperidone acts as a peripheral antiemetic and prokinetic agent by antagonizing dopamine D2 receptors in the chemoreceptor trigger zone and the upper gastrointestinal tract. This action helps alleviate migraine-associated nausea and vomiting and may counteract gastric stasis, potentially improving the absorption and efficacy of the analgesic component. The combination is specifically indicated for the acute treatment of migraine attacks where nausea is a prominent symptom.
- Brand names
- NAPRO-D
- Other names
- naproxen and domperidone combination
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DRD2 (Dopamine D2 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on naproxen + domperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naproxen + domperidone.